Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:KRYS NYSE:NUVB NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$77.86-2.7%$71.68$47.86▼$107.37$4.32B0.28508,098 shs825,799 shsKRYSKrystal Biotech$163.57+1.8%$147.98$122.80▼$207.84$4.73B0.66307,170 shs811,005 shsNUVBNuvation Bio$3.21+1.3%$2.75$1.54▼$4.09$1.10B1.366.76 million shs7.67 million shsPCVXVaxcyte$31.75-2.6%$32.84$27.66▼$118.62$4.12B1.041.60 million shs4.06 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%+2.19%+8.49%+23.59%-3.34%KRYSKrystal Biotech0.00%+13.84%+12.26%+23.49%-10.49%NUVBNuvation Bio0.00%+2.23%+17.37%+64.19%+10.69%PCVXVaxcyte0.00%-1.31%-0.50%-3.41%-72.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$77.86-2.7%$71.68$47.86▼$107.37$4.32B0.28508,098 shs825,799 shsKRYSKrystal Biotech$163.57+1.8%$147.98$122.80▼$207.84$4.73B0.66307,170 shs811,005 shsNUVBNuvation Bio$3.21+1.3%$2.75$1.54▼$4.09$1.10B1.366.76 million shs7.67 million shsPCVXVaxcyte$31.75-2.6%$32.84$27.66▼$118.62$4.12B1.041.60 million shs4.06 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%+2.19%+8.49%+23.59%-3.34%KRYSKrystal Biotech0.00%+13.84%+12.26%+23.49%-10.49%NUVBNuvation Bio0.00%+2.23%+17.37%+64.19%+10.69%PCVXVaxcyte0.00%-1.31%-0.50%-3.41%-72.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.13Buy$114.3146.81% UpsideKRYSKrystal Biotech 2.86Moderate Buy$209.0027.77% UpsideNUVBNuvation Bio 3.17Buy$7.50133.64% UpsidePCVXVaxcyte 3.00Buy$106.25234.65% UpsideCurrent Analyst Ratings BreakdownLatest NUVB, ACLX, PCVX, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/19/2025NUVBNuvation BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.009/15/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$240.009/12/2025PCVXVaxcyteThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$38.009/8/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$6.008/22/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$219.00 ➝ $216.008/22/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$240.008/8/2025NUVBNuvation BioRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $7.008/7/2025PCVXVaxcyteCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/5/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$176.00 ➝ $166.008/5/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$219.008/4/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M40.00N/AN/A$8.41 per share9.26KRYSKrystal Biotech$290.52M16.29$4.64 per share35.27$32.90 per share4.97NUVBNuvation Bio$7.87M139.60N/AN/A$1.37 per share2.34PCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%11/6/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.9233.2516.23N/A40.85%15.21%13.81%11/3/2025 (Estimated)NUVBNuvation Bio-$567.94M-$0.63N/AN/AN/A-1,413.43%-46.14%-36.04%11/5/2025 (Estimated)PCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)Latest NUVB, ACLX, PCVX, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/7/2025Q2 2025NUVBNuvation Bio-$0.17-$0.17N/A-$0.17$0.42 million$4.83 million8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A3.813.81KRYSKrystal BiotechN/A9.689.33NUVBNuvation Bio0.139.399.38PCVXVaxcyteN/A11.1111.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%KRYSKrystal Biotech86.29%NUVBNuvation Bio61.67%PCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%KRYSKrystal Biotech13.70%NUVBNuvation Bio29.93%PCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.46 million50.83 millionOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionableNUVBNuvation Bio60342.27 million239.83 millionOptionablePCVXVaxcyte160129.82 million125.80 millionOptionableNUVB, ACLX, PCVX, and KRYS HeadlinesRecent News About These CompaniesStrs Ohio Buys Shares of 16,600 Vaxcyte, Inc. $PCVX2 hours ago | marketbeat.comHarbor Capital Advisors Inc. Buys 25,303 Shares of Vaxcyte, Inc. $PCVXSeptember 18 at 4:36 AM | marketbeat.comVaxcyte, Inc. $PCVX Shares Acquired by Rhumbline AdvisersSeptember 15, 2025 | marketbeat.comVaxcyte, Inc. $PCVX Stock Position Increased by Intech Investment Management LLCSeptember 15, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 15, 2025 | marketbeat.comThe Goldman Sachs Group Begins Coverage on Vaxcyte (NASDAQ:PCVX)September 14, 2025 | marketbeat.comVaxcyte (NASDAQ:PCVX) Earns Neutral Rating from Analysts at The Goldman Sachs GroupSeptember 14, 2025 | americanbankingnews.comGoldman Sachs Initiates Coverage of Vaxcyte (PCVX) with Neutral RecommendationSeptember 13, 2025 | msn.comVaxcyte initiated with a Neutral at Goldman SachsSeptember 12, 2025 | msn.comTSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than CompellingSeptember 12, 2025 | msn.comWoodline Partners LP Has $41.98 Million Stock Position in Vaxcyte, Inc. $PCVXSeptember 12, 2025 | marketbeat.comFred Alger Management LLC Has $844,000 Stake in Vaxcyte, Inc. $PCVXSeptember 12, 2025 | marketbeat.comJones Financial Companies Lllp Has $6.27 Million Stock Holdings in Vaxcyte, Inc. $PCVXSeptember 12, 2025 | marketbeat.comAmundi Sells 63,416 Shares of Vaxcyte, Inc. $PCVXSeptember 12, 2025 | marketbeat.comPolar Asset Management Partners Inc. Acquires Shares of 10,004 Vaxcyte, Inc. $PCVXSeptember 9, 2025 | marketbeat.comAlliancebernstein L.P. Sells 75,151 Shares of Vaxcyte, Inc. $PCVXSeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $3.53 Million Stake in Vaxcyte, Inc. $PCVXSeptember 8, 2025 | marketbeat.comAlyeska Investment Group L.P. Sells 32,945 Shares of Vaxcyte, Inc. $PCVXSeptember 8, 2025 | marketbeat.comVaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comEventide Asset Management LLC Purchases 86,776 Shares of Vaxcyte, Inc. $PCVXSeptember 6, 2025 | marketbeat.comCormorant Asset Management LP Reduces Stock Position in Vaxcyte, Inc. $PCVXSeptember 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNUVB, ACLX, PCVX, and KRYS Company DescriptionsArcellx NASDAQ:ACLX$77.86 -2.12 (-2.65%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$77.84 -0.02 (-0.03%) As of 09/19/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Krystal Biotech NASDAQ:KRYS$163.57 +2.96 (+1.84%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$165.44 +1.87 (+1.14%) As of 09/19/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nuvation Bio NYSE:NUVB$3.21 +0.04 (+1.26%) Closing price 09/19/2025 03:59 PM EasternExtended Trading$3.22 +0.00 (+0.16%) As of 09/19/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Vaxcyte NASDAQ:PCVX$31.75 -0.84 (-2.58%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$32.39 +0.64 (+2.02%) As of 09/19/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
